Home > > Middle East & Africa And Global Direct to Consumer Genetic Testing Market- Size, Share, Growth Rate, and Forecast
The Middle East & Africa Direct to Consumer Genetic Testing market was valued at $44,342.3 Million in 2023, and is projected to reach $52,202.0 Million by 2030 growing at a CAGR of 2.41% from 2024 to 2030. Clinical Chemistry segment is expected to be the highest contributor to this market, with $20,262.2 Million in 2023, and is anticipated to reach $24,232.5 by 2030, registering a CAGR of 2.64%. Human & Tumor Genetics segment is anticipated to reach $13,167.1 Million by 2030 with the highest CAGR of 2.73%. Clinical Chemistry and Human & Tumor Genetics segments collectively expected to account for about 70.4% share of the Middle East & Africa Direct to Consumer Genetic Testing market in 2023, with the former constituting around 45.7% share. Human & Tumor Genetics and Clinical Chemistry segments are expected to witness significant growth rates at a CAGR of 2.73% and 2.64% respectively, during the forecast period. Presently, share of these two segments is estimated to be around 70.4% in the overall Middle East & Africa Direct to Consumer Genetic Testing market in 2023, and is anticipated to reach 71.6% by 2030. Test Type Human & Tumor Genetics Clinical Chemistry Medical Microbiology & Cytology Other Test Types Service provider Hospital-based Laboratories Stand-alone Laboratories Clinic-based Laboratories BY REGION North America U.s. Canada Mexico Europe Germany France U.k. Italy Spain Russia Rest of Europe Asia China India Japan Australia Rest of Asia Middle East & Africa Brazil South Africa GCC Rest of MENA